InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the full record of transactions filed by Aker Christopher Ray, Vice-Président Senior et Conseiller Juridique Général. Insider active across 2 companies, notably Regulus Therapeutics Inc.. Aggregated, 6 filings have been recorded. Split: 0 buy · 4 sells. Total volume traded: €55k. History available since 17 May 2021. The latest transaction was disclosed on 13 January 2025 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations6 total
38,547 shares@ US$1.263233.5% of flowCommon StockSEC:0000950170-25-005882:0
66,625 shares@ US$1.3661.9% of flowCommon StockSEC:0000950170-25-004270:0
5,468 shares@ US$1.19064.2% of flowCommon StockSEC:0001209191-24-001874:0
11,250 shares0Common StockSEC:0001209191-24-001771:0
860 shares@ US$0.89100.0% of flowCommon StockSEC:0001209191-21-033296
860 shares@ US$0.89100.0% of flowCommon StockSEC:0001209191-21-033296:0
6 of 6 declarations
About Aker Christopher Ray
Christopher Ray Aker is the Senior Vice President and General Counsel at Regulus Therapeutics Inc. He is responsible for managing the company's legal affairs, including regulatory compliance and intellectual property protection. His expertise in business law and regulation is essential to support Regulus Therapeutics' mission.
